3Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart diease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther, 1998,63: 519-528.
4St John Sutton MG. Anticoagulants and the Bjork-Shiley prosthesis. Experience of 390 patients. Br Heart J, 1978,40:558-561.
5Yu HCM, Chan TYK, Critchley JAJH, et al. Factors determining the maintenance dose of warfarin in Chinese patients. Q J Med, 1996,89: 127-128.
6Andalibi P, Farsam H, Amanlou M,et al. Determination of dosage requirements of warfarin in iranian patients using HPLC technique. J Clin Pharm Ther, 1998,23:199-202.
7Poller L, Taberher DA. Dosgae and control of oral anticogulants: an international collaborative surve. Br J Haematol, 1982.51:479-485.
8Evans DI, Rowlands M, Poller L. Survey of oral anticogulant treetment in children. J Clin Pathol, 1992,45: 707 -708.
9Fiane AE, Lindberg HL, Saatvedt K, et al. Mechanical valve replacement in congenital heart disease. J Heart Valve Dis, 1996,5:337-342.
10Pifarre R.Thrombosis and cardiovascular disease. Med Clin North Am, 1998,82:511-522.
